|
HS Code |
480836 |
| Chemical Name | 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide |
| Molecular Formula | C9H16N3·2HBr |
| Molecular Weight | 345.08 g/mol |
| Appearance | White to off-white solid |
| Cas Number | NA |
| Solubility | Soluble in water |
| Storage Conditions | Store at 2-8°C, protected from light and moisture |
| Purity | Typically ≥98% |
| Synonyms | 4-(4-Methyl-1H-imidazol-1-yl)piperidine dihydrobromide |
| Smiles | C1CN(CCC1)Cc2cncn2.Br.Br |
| Application | Research chemical, potential pharmacological tool |
As an accredited 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | |
| Shipping | |
| Storage |
Competitive 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615371019725 or mail to admin@sinochem-nanjing.com.
We will respond to you as soon as possible.
Tel: +8615371019725
Email: admin@sinochem-nanjing.com
Flexible payment, competitive price, premium service - Inquire now!
Chemists and pharmaceutical researchers know how tough it can get to track down compounds that unlock new possibilities in the lab. Not every reagent stands up to the task—especially when precision and purity make all the difference in results. One compound that’s been drawing more attention lately is 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide. Unlike a generic building block, this molecule offers several advantages when a project hinges on exact molecular structure and reactivity—especially in medicinal chemistry, where each component can push research a step forward or leave it stuck in the weeds.
This compound combines a piperidine ring and an imidazole group, joined by a methyl bridge. Both parts bring specific reactivity and binding potential. Piperidine rings appear often in pharmaceuticals and bioactive molecules because their shape and electron distribution match up well with many biological targets. The imidazole ring offers its own unique contribution: it often acts in binding sites throughout biological systems, including enzyme active sites and receptor domains. Together, this creates a versatile starting point for molecular innovation. The dihydrobromide salt form of this molecule gives enhanced solubility and stability, cutting down the chance of experimental headaches caused by clumping, precipitation, or inconsistent dosing.
Plenty of piperidine and imidazole derivatives fill catalogues. What makes 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide more helpful in some settings starts with the unique way its two active regions are linked. Synthetic chemists can capitalize on this structure for targeted modifications, letting them test subtle variations on drug candidates or probe molecular interactions at a finer level than with bulkier, less flexible alternatives. Compared to similar compounds without the methyl bridge or the refined salt form, this molecule behaves with greater predictability in reaction setups. That reliability doesn’t just ease the mental load—it means fewer failed batches, less troubleshooting, and tighter research timelines.
Experimental chemistry depends on more than just theory. In my own work, keeping reactions consistent across a week or a month often comes down to little differences in input materials. Salts like this one help because their crystalline nature makes it easier to weigh out small, reproducible amounts. Dihydrobromide salts tend to dissolve better in water and mixed solvents than their free base counterparts, which can reduce clumping and variability. Less time is wasted tracking down the source of differences between batches or chasing odd peaks on spectra.
When you’re putting together a multi-step synthesis for a new drug candidate, mistakes in a single intermediate compound can cascade through the entire project. I’ve learned the hard way that the more stable and pure the input, the fewer unexpected surprises crop up downstream. This reliability is the kind of peace of mind that can’t be quantified—especially with grant deadlines looming or when trying to match published protocols.
Pharmaceutical research focuses more than ever on small molecules with high selectivity and stability. This compound’s design aligns well with those needs. Whether the end goal is targeting neurological conditions or fine-tuning another class of bioactive molecules, the piperidine-imidazole core acts as a starting point for even more complex structures. Medicinal chemists spend huge chunks of time searching for lead compounds—they need building blocks that don’t just work on paper but integrate smoothly into larger molecules. I remember collaborating on a project aimed at inhibiting a certain class of protein kinases. The subtle interaction between the imidazole nitrogen atom and enzymatic pockets directly affected biological activity. Swapping in a different linker or ring system threw off the whole effort, but using this specific piperidine-imidazole arrangement gave us a shot at high binding affinity and improved selectivity.
Some might try to get away with cheaper, less refined analogs at the start of a project, especially during broad screenings. That shortcut piles up issues fast as the project moves into optimization. Unknown impurities and batch-to-batch variation force researchers to spend weeks untangling which outcomes stem from the compound and which belong to contamination or side reactions. I have seen teams waste a whole semester chasing ghosts that only show up because the starting material let them down.
It’s tempting to group imidazole and piperidine derivatives together and treat them as interchangeable. Anyone who’s spent time doing hands-on synthesis work can point to reasons why this doesn’t always hold. The methyl bridge not only enables predictable reactivity with nucleophiles and electrophiles but also tunes the physical characteristics of the compound—solubility, melting point, and even how it handles during weighing or dissolution. Dihydrobromide salts such as this tend to fare better under long-term storage and climate fluctuations, which is crucial in labs without specialized climate control. In contrast, free bases may absorb moisture or degrade, leading to inconsistent results.
I’ve come across lesser-known salt forms with the same backbone structure. Those don’t always deliver the same balance of ease and reliability. Hydrochloride salts, for example, might be cheaper, but they often show reduced solubility in mixed solvents or exhibit sensitivity to pH swings that don’t disrupt the dihydrobromide version. With a limited amount of precious starting material and a series of costly steps ahead, these small differences add up quickly in both cost and frustration.
Research progress stalls out fast when there’s uncertainty about what sits in the vial. Analytical validation, including NMR, HPLC, or MS, keeps scientists honest. Suppliers who provide 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide with full certificates of analysis and batch records ensure that labs can trust every milligram. This isn’t about paperwork; teams count on knowing what changes a batch caused, not what an untracked contaminant created. While some colleagues like to cut corners at the procurement step, years of troubleshooting tough projects tell me it rarely pays off. Reliable data depends on reliable sourcing, and the extra attention to detail at this stage safeguards months of effort down the line.
It’s easy to underestimate the importance of predictable handling in developing molecules. Many base forms of piperidine derivatives carry strong odors or volatile properties that complicate routine lab work. Dihydrobromide salts, such as this one, handle with less fuss. The salt form achieves more stable storage, less hazardous inhalation risk, and simplified cleaning after experiments. Reducing these pain points supports lab safety guidelines and lets teams focus energy on research rather than housekeeping.
Standardized forms also streamline compliance with institutional and government safety protocols. There’s less ambiguity facing safety officers or regulatory reviews when a compound matches well-known profiles. Fewer surprises in the stockroom lead to a safer, more productive lab.
Modern labs must confront environmental and sustainability concerns with every new reagent. Dihydrobromide salts typically show better stability, reducing the need for frequent reordering and disposal of degraded stock. Over months or years of research, the waste from spoiled or contaminated input material totals far more than a single lab budget reflects. Teams looking to minimize environmental impact get an edge from reagents that stay shelf-stable and don’t need repeated replacements.
Chemical waste management is another reality that never goes away. Each time starting materials spoil prematurely, those leftovers become hazardous waste that needs careful disposal. By supporting compound choices with better handling and predictable longevity, teams can avoid both wasted money and unnecessary environmental burden.
I’ve lost count of how many projects grind to a halt not because of an idea that won’t work but because an intermediate failed to deliver the necessary purity or physical stability. Scientists keep timelines tight using reagents that reduce the risk of side products and degradation during synthetic steps. The piperidine-imidazole skeleton at the core of this compound fits well with a range of popular medicinal scaffolds and does so without introducing excessive steric bulk or metabolic instability.
Even small differences in physical properties can change the time required for purification, troubleshooting, and analysis. Salt forms like the dihydrobromide provide more predictable crystallization and isolation during synthesis. This cuts down on wasted time and resources. Over the years, I’ve sat through enough project post-mortems to know that thoughtful selection at the earliest stage saves weeks (sometimes months) of cleanup and repeat experiments.
Multi-investigator projects rely on shared reagents behaving the same way in different hands. This means everyone, from structural biologists to cell-based assay teams, can trust that what they have matches what their collaborators use. Salt forms with standardized handling and reactivity, such as 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide, promote this necessary consistency. Teams spend less effort cross-checking whether one group’s failure resulted from procedural or material differences. As collaborative science grows in importance—especially in industry-led drug discovery—choosing reliable, well-characterized inputs becomes key for progress.
Between data sharing, outsourced synthesis, and remote collaboration, widely recognized compounds provide a shared foundation. They support harmonized protocols and limit variables that can obscure genuine findings. I’ve watched this play out in multi-site projects for antimicrobial agents and neuroactive compounds, where having a reproducible, well-documented starting material improved communication as well as results.
A single well-designed reagent can unlock years of downstream research. The core piperidine-imidazole structure welcomes selective modification, whether through N-alkylation, acylation, or functionalization of the imidazole ring. Some groups use this molecule to craft intermediates for receptor ligand studies, while others explore analogs for metabolic or pharmacokinetic tuning. Customizing just one region sometimes brings a molecule from preclinical studies to lead optimization without changing the rest of the system.
Projects focused on structure-activity relationships depend on the kind of modular scaffold found here. Teams can quickly generate analog libraries by tweaking substituents on either ring. The salt form’s reactivity profile encourages confidence that core modifications won’t be obscured by decomposition or hard-to-isolate impurities. Experience shows that the stability and transparency of each synthetic step drive more reliable structure-activity data.
Drug discovery and materials science aren’t slowing down. As new disease targets and bioactive pathways come into focus each year, the need for thoughtfully chosen building blocks only grows. Chemicals like 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide set a benchmark for research reliability—where input predictability translates into clearer outputs and faster progress. Predictable reactions save time, but more importantly, they help teams interpret results with less lingering doubt about underlying causes.
Older, less refined materials introduced too many variables to complex syntheses. Chemists often had to write off whole series of experiments and move back to more expensive or less efficient steps just to regain control. With today’s more robust and thoroughly characterized compounds, teams remain focused on exploring chemical space instead of fighting fires created by erratic input.
It’s tough to justify investing in higher-quality reagents at the start, especially for exploratory projects. Research budgets run tight. The temptation to cut corners can lead down a path riddled with repeat work and inconsistent findings. Labs that consistently invest in reliable building blocks—rather than chasing the cheapest initial buy—find their long-term project costs and timelines drop. Scale-up from milligram to gram quantities throws new complications into the mix. Slight differences in solvent interactions, batch purity, or salt form can make forgiving reactions suddenly unpredictable.
To keep these scale-up nightmares at bay, I’ve worked with procurement teams who demand up-to-date certificates of analysis, comprehensive QC data, and detailed shipment records. This isn’t bureaucracy for bureaucracy’s sake. It means that surprises at the bench are less likely to trace back to corner-cutting earlier in the supply chain. Teams keep research hours focused on real discoveries instead of damage control.
Years spent at the chemistry bench teach more than just technical procedures. They highlight how fragile a project’s timeline and data quality become with unpredictable or poorly handled reagents. Choosing compounds with known pedigree, robust salt forms, and strong physical properties has repeatedly set successful projects apart from those that never quite get off the ground. In a climate where grant money grows hard to win, and publication standards climb, investing in the right tools pays back with every successful experiment and valid data point.
No single reagent makes or breaks a program. Yet the downstream effects of a good—or bad—choice compound ripple out through months or years. In the high-stakes world of drug discovery, chemical development, and interdisciplinary science, embracing building blocks like 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide can mean the difference between a spectacular launch and a series of disappointing setbacks. On a personal level, I’d rather place bets on reliability than risk short-term savings which cost far more later.
The best advances in research depend on a foundation of purpose-built, thoroughly vetted components. Choosing a compound with standout properties—both in terms of its chemistry and real-world handling—sets the stage for innovation at every level. While plenty of alternatives can be found, few provide the rare blend of versatility, purity, and ease that comes with 4-(1H-Imidazolyl-4-Methyl)Piperidine Dihydrobromide. Having the confidence that each new experiment starts from a solid place frees teams from troubleshooting minor setbacks and lets them focus on bigger breakthroughs, pushing research toward real-world solutions.